| 1st level
|
2nd level
|
3rd level
|
4th level
|
5th level
|
Contents
|
| A
|
|
|
|
|
Alimentary tract and metabolism
|
|
|
A01
|
|
|
|
Stomatological preparations
|
|
|
|
A01A
|
|
|
Stomatological preparations
|
|
|
|
|
A01AA
|
|
Caries prophylactic agents
|
|
|
|
|
|
A01AA01
|
Sodium fluoride
|
|
|
|
|
|
A01AA02
|
Sodium monofluorophosphate
|
|
|
|
|
|
A01AA03
|
Olaflur
|
|
|
|
|
|
A01AA04
|
Stannous fluoride
|
|
|
|
|
|
A01AA30
|
Combinations
|
|
|
|
|
|
A01AA51
|
Sodium fluoride, combinations
|
|
|
|
|
A01AB
|
|
Anti-infectives and antiseptics for local oral treatment
|
|
|
|
|
|
A01AB02
|
Hydrogen peroxide
|
|
|
|
|
|
A01AB03
|
Chlorhexidine
|
|
|
|
|
|
A01AB04
|
Amphotericin B
|
|
|
|
|
|
A01AB05
|
Polynoxylin
|
|
|
|
|
|
A01AB06
|
Domiphen
|
|
|
|
|
|
A01AB07
|
Oxyquinoline
|
|
|
|
|
|
A01AB08
|
Neomycin
|
|
|
|
|
|
A01AB09
|
Miconazole
|
|
|
|
|
|
A01AB10
|
Natamycin
|
|
|
|
|
|
A01AB11
|
Various
|
|
|
|
|
|
A01AB12
|
Hexetidine
|
|
|
|
|
|
A01AB13
|
Tetracycline
|
|
|
|
|
|
A01AB14
|
Benzoxonium chloride
|
|
|
|
|
|
A01AB15
|
Tibezonium iodide
|
|
|
|
|
|
A01AB16
|
Mepartricin
|
|
|
|
|
|
A01AB17
|
Metronidazole
|
|
|
|
|
|
A01AB18
|
Clotrimazole
|
|
|
|
|
|
A01AB19
|
Sodium perborate
|
|
|
|
|
|
A01AB21
|
Chlortetracycline
|
|
|
|
|
|
A01AB22
|
Doxycycline
|
|
|
|
|
|
A01AB23
|
Minocycline
|
|
|
|
|
A01AC
|
|
Corticosteroids for local oral treatment
|
|
|
|
|
|
A01AC01
|
Triamcinolone
|
|
|
|
|
|
A01AC02
|
Dexamethasone
|
|
|
|
|
|
A01AC03
|
Hydrocortisone
|
|
|
|
|
|
A01AC54
|
Prednisolone, combinations
|
|
|
|
|
A01AD
|
|
Other agents for local oral treatment
|
|
|
|
|
|
A01AD01
|
Epinephrine
|
|
|
|
|
|
A01AD02
|
Benzydamine
|
|
|
|
|
|
A01AD05
|
Acetylsalicylic acid
|
|
|
|
|
|
A01AD06
|
Adrenalone
|
|
|
|
|
|
A01AD07
|
Amlexanox
|
|
|
|
|
|
A01AD08
|
Becaplermin
|
|
|
|
|
|
A01AD11
|
Various
|
|
|
A02
|
|
|
|
Drugs for acid related disorders
|
|
|
|
A02A
|
|
|
Antacids
|
|
|
|
|
A02AA
|
|
Magnesium compounds
|
|
|
|
|
|
A02AA01
|
Magnesium carbonate
|
|
|
|
|
|
A02AA02
|
Magnesium oxide
|
|
|
|
|
|
A02AA03
|
Magnesium peroxide
|
|
|
|
|
|
A02AA04
|
Magnesium hydroxide
|
|
|
|
|
|
A02AA05
|
Magnesium silicate
|
|
|
|
|
|
A02AA10
|
Combinations
|
|
|
|
|
A02AB
|
|
Aluminium compounds
|
|
|
|
|
|
A02AB01
|
Aluminium hydroxide
|
|
|
|
|
|
A02AB02
|
Algeldrate
|
|
|
|
|
|
A02AB03
|
Aluminium phosphate
|
|
|
|
|
|
A02AB04
|
Dihydroxialumini sodium carbonate
|
|
|
|
|
|
A02AB05
|
Aluminium acetoacetate
|
|
|
|
|
|
A02AB06
|
Aloglutamol
|
|
|
|
|
|
A02AB07
|
Aluminium glycinate
|
|
|
|
|
|
A02AB10
|
Combinations
|
|
|
|
|
A02AC
|
|
Calcium compounds
|
|
|
|
|
|
A02AC01
|
Calcium carbonate
|
|
|
|
|
|
A02AC02
|
Calcium silicate
|
|
|
|
|
|
A02AC10
|
Combinations
|
|
|
|
|
A02AD
|
|
Combinations and complexes of aluminium, calcium and magnesium compounds
|
|
|
|
|
|
A02AD01
|
Ordinary salt combinations
|
|
|
|
|
|
A02AD02
|
Magaldrate
|
|
|
|
|
|
A02AD03
|
Almagate
|
|
|
|
|
|
A02AD04
|
Hydrotalcite
|
|
|
|
|
|
A02AD05
|
Almasilate
|
|
|
|
|
A02AF
|
|
Antacids with antiflatulents
|
|
|
|
|
|
A02AF01
|
Magaldrate and antiflatulents
|
|
|
|
|
|
A02AF02
|
Ordinary salt combinations and antiflatulents
|
|
|
|
|
A02AG
|
|
Antacids with antispasmodics
|
|
|
|
|
A02AH
|
|
Antacids with sodium bicarbonate
|
|
|
|
|
A02AX
|
|
Antacids, other combinations
|
|
|
|
A02B
|
|
|
Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD)
|
|
|
|
|
A02BA
|
|
H2-receptor antagonists
|
|
|
|
|
|
A02BA01
|
Cimetidine
|
|
|
|
|
|
A02BA02
|
Ranitidine
|
|
|
|
|
|
A02BA03
|
Famotidine
|
|
|
|
|
|
A02BA04
|
Nizatidine
|
|
|
|
|
|
A02BA05
|
Niperotidine
|
|
|
|
|
|
A02BA06
|
Roxatidine
|
|
|
|
|
|
A02BA07
|
Ranitidine bismuth citrate
|
|
|
|
|
|
A02BA08
|
Lafutidine
|
|
|
|
|
|
A02BA51
|
Cimetidine, combinations
|
|
|
|
|
|
A02BA53
|
Famotidine, combinations
|
|
|
|
|
A02BB
|
|
Prostaglandins
|
|
|
|
|
|
A02BB01
|
Misoprostol
|
|
|
|
|
|
A02BB02
|
Enprostil
|
|
|
|
|
A02BC
|
|
Proton pump inhibitors
|
|
|
|
|
|
A02BC01
|
Omeprazole
|
|
|
|
|
|
A02BC02
|
Pantoprazole
|
|
|
|
|
|
A02BC03
|
Lansoprazole
|
|
|
|
|
|
A02BC04
|
Rabeprazole
|
|
|
|
|
|
A02BC05
|
Esomeprazole
|
|
|
|
|
|
A02BC06
|
Dexlansoprazole
|
|
|
|
|
A02BD
|
|
Combinations for eradication of Helicobacter pylori
|
|
|
|
|
|
A02BD01
|
Omeprazole, amoxicillin and metronidazole
|
|
|
|
|
|
A02BD02
|
Lansoprazole, tetracycline and metronidazole
|
|
|
|
|
|
A02BD03
|
Lansoprazole, amoxicillin and metronidazole
|
|
|
|
|
|
A02BD04
|
Pantoprazole, amoxicillin and clarithromycin
|
|
|
|
|
|
A02BD05
|
Omeprazole, amoxicillin and clarithromycin
|
|
|
|
|
|
A02BD06
|
Esomeprazole, amoxicillin and clarithromycin
|
|
|
|
|
|
A02BD07
|
Lansoprazole, amoxicillin and clarithromycin
|
|
|
|
|
|
A02BD08
|
Bismuth subcitrate, tetracycline and metronidazole
|
|
|
|
|
A02BX
|
|
Other drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD)
|
|
|
|
|
|
A02BX01
|
Carbenoxolone
|
|
|
|
|
|
A02BX02
|
Sucralfate
|
|
|
|
|
|
A02BX03
|
Pirenzepine
|
|
|
|
|
|
A02BX04
|
Methiosulfonium chloride
|
|
|
|
|
|
A02BX05
|
Bismuth subcitrate
|
|
|
|
|
|
A02BX06
|
Proglumide
|
|
|
|
|
|
A02BX07
|
Gefarnate
|
|
|
|
|
|
A02BX08
|
Sulglicotide
|
|
|
|
|
|
A02BX09
|
Acetoxolone
|
|
|
|
|
|
A02BX10
|
Zolimidine
|
|
|
|
|
|
A02BX11
|
Troxipide
|
|
|
|
|
|
A02BX12
|
Bismuth subnitrate
|
|
|
|
|
|
A02BX13
|
Alginic acid
|
|
|
|
|
|
A02BX51
|
Carbenoxolone, combinations excluding psycholeptics
|
|
|
|
|
|
A02BX71
|
Carbenoxolone, combinations with psycholeptics
|
|
|
|
|
|
A02BX77
|
Gefarnate, combinations with psycholeptics
|
|
|
|
A02X
|
|
|
Other drugs for acid related disorders
|
|
|
A03
|
|
|
|
Drugs for functional gastrointestinal disorders
|
|
|
A04
|
|
|
|
Antiemetics and antinauseants
|
|
|
A05
|
|
|
|
Bile and liver therapy
|
|
|
A06
|
|
|
|
Drugs for constipation
|
|
|
A07
|
|
|
|
Antidiarrheals, intestinal anti-inflammatory/anti-infective agents
|
|
|
A08
|
|
|
|
Antiobesity preparations, excluding diet products
|
|
|
A09
|
|
|
|
Digestives,including enzymes
|
|
|
A10
|
|
|
|
Drugs used in diabetes
|
|
|
A11
|
|
|
|
Vitamins
|
|
|
A12
|
|
|
|
Mineral supplements
|
|
|
A13
|
|
|
|
Tonics
|
|
|
A14
|
|
|
|
Anabolic agents for systemic use
|
|
|
A15
|
|
|
|
Appetite stimulants
|
|
|
A16
|
|
|
|
Other alimentary tract and metabolism products
|
| B
|
|
|
|
|
Blood and blood forming organs
|
| C
|
|
|
|
|
Cardiovascular system
|
|
|
C01
|
|
|
|
Cardiac therapy
|
|
|
C02
|
|
|
|
Antihypertensives
|
|
|
C03
|
|
|
|
Diuretics
|
|
|
C04
|
|
|
|
Peripheral vasodilators
|
|
|
C05
|
|
|
|
Vasoprotectives
|
|
|
C07
|
|
|
|
Beta blocking agents
|
|
|
C08
|
|
|
|
Calcium channel blockers
|
|
|
C09
|
|
|
|
Agents acting on the renin-angiotensin system
|
|
|
C10
|
|
|
|
Lipid modifying agents
|
|
|
|
C10A
|
|
|
Lipid modifying agents, plain
|
|
|
|
|
C10AA
|
|
HMG CoA reductase inhibitors
|
|
|
|
|
C10AB
|
|
Fibrates
|
|
|
|
|
C10AC
|
|
Bile acid sequestrants
|
|
|
|
|
|
C10AC01
|
Colestyramine
|
|
|
|
|
|
C10AC02
|
Colestipol
|
|
|
|
|
|
C10AC03
|
Colextran
|
|
|
|
|
|
C10AC04
|
Colesevelam
|
|
|
|
|
C10AD
|
|
Nicotinic acid and derivatives
|
|
|
|
|
C10AX
|
|
Other lipid modifying agents
|
|
|
|
C10B
|
|
|
Lipid modifying agents, combinations
|
| D
|
|
|
|
|
Dermatologicals
|
| G
|
|
|
|
|
Genito-urinary system and sex hormones
|
| H
|
|
|
|
|
Systemic hormonal preparations, excluding sex hormones and insulins
|
| J
|
|
|
|
|
Antiinfectives for systemic use
|
|
|
J01
|
|
|
|
Antibacterials for systemic use
|
|
|
J02
|
|
|
|
Antimycotics for systemic use
|
|
|
J04
|
|
|
|
Antimycobacterials
|
|
|
J05
|
|
|
|
Antivirals for systemic use
|
|
|
|
J05A
|
|
|
Direct acting antiviral drugs
|
|
|
|
|
J05AA
|
|
Thiosemicarbazones
|
|
|
|
|
J05AB
|
|
Nucleosides and nucleotides excluding reverse transcriptase inhibitors
|
|
|
|
|
J05AC
|
|
Cyclic amines
|
|
|
|
|
J05AD
|
|
Phosphonic acid derivatives
|
|
|
|
|
J05AE
|
|
Protease inhibitors
|
|
|
|
|
J05AF
|
|
Nucleoside and nucleotide reverse transcriptase inhibitors
|
|
|
|
|
|
J05AF01
|
Zidovudine
|
|
|
|
|
|
J05AF02
|
Didanosine
|
|
|
|
|
|
J05AF03
|
Zalcitabine
|
|
|
|
|
|
J05AF04
|
Stavudine
|
|
|
|
|
|
J05AF05
|
Lamivudine
|
|
|
|
|
|
J05AF06
|
Abacavir
|
|
|
|
|
|
J05AF07
|
Tenofovir disoproxil
|
|
|
|
|
|
J05AF08
|
Adefovir dipivoxil
|
|
|
|
|
|
J05AF09
|
Emtricitabine
|
|
|
|
|
|
J05AF10
|
Entecavir
|
|
|
|
|
|
J05AF11
|
Telbivudine
|
|
|
|
|
|
J05AF12
|
Clevudine
|
|
|
|
|
J05AG
|
|
Non-nucleoside reverse transcriptase inhibitors
|
|
|
|
|
J05AH
|
|
Neuraminidase inhibitors
|
|
|
|
|
J05AR
|
|
Antivirals for treatment of HIV infections, combinations
|
|
|
|
|
J05AX
|
|
Other antivirals
|
|
|
J06
|
|
|
|
Immune sera and immunoglobulins
|
|
|
|
J06A
|
|
|
Immune sera
|
|
|
|
|
J06AA
|
|
Immune sera
|
|
|
|
|
|
J06AA01
|
Diphtheria antitoxin
|
|
|
|
|
|
J06AA02
|
Tetanus antitoxin
|
|
|
|
|
|
J06AA03
|
Snake venom antiserum
|
|
|
|
|
|
J06AA04
|
Botulinum antitoxin
|
|
|
|
|
|
J06AA05
|
Gas-gangrene sera
|
|
|
|
|
|
J06AA06
|
Rabies serum
|
|
|
|
J06B
|
|
|
Immunoglobulins
|
|
|
|
|
J06BA
|
|
Immunoglobulins, normal human
|
|
|
|
|
|
J06BA01
|
Immunoglobulins, normal human, for extravascular administration
|
|
|
|
|
|
J06BA02
|
Immunoglobulins, normal human, for intravascular administration
|
|
|
|
|
J06BB
|
|
Specific immunoglobulins
|
|
|
|
|
|
J06BB01
|
Anti-D (rh) immunoglobulin
|
|
|
|
|
|
J06BB02
|
Tetanus immunoglobulin
|
|
|
|
|
|
J06BB03
|
Varicella/zoster immunoglobulin
|
|
|
|
|
|
J06BB04
|
Hepatitis B immunoglobulin
|
|
|
|
|
|
J06BB05
|
Rabies immunoglobulin
|
|
|
|
|
|
J06BB06
|
Rubella immunoglobulin
|
|
|
|
|
|
J06BB07
|
Vaccinia immunoglobulin
|
|
|
|
|
|
J06BB08
|
Staphylococcus immunoglobulin
|
|
|
|
|
|
J06BB09
|
Cytomegalovirus immunoglobulin
|
|
|
|
|
|
J06BB10
|
Diphtheria immunoglobulin
|
|
|
|
|
|
J06BB11
|
Hepatitis A immunoglobulin
|
|
|
|
|
|
J06BB12
|
Encephalitis, tick borne immunoglobulin
|
|
|
|
|
|
J06BB13
|
Pertussis immunoglobulin
|
|
|
|
|
|
J06BB14
|
Morbilli immunoglobulin
|
|
|
|
|
|
J06BB15
|
Parotitis immunoglobulin
|
|
|
|
|
|
J06BB16
|
Palivizumab
|
|
|
|
|
|
J06BB17
|
Motavizumab
|
|
|
|
|
|
J06BB30
|
Combinations
|
|
|
|
|
J06BC
|
|
Other immunoglobulins
|
|
|
|
|
|
J06BC01
|
Nebacumab
|
| L
|
|
|
|
|
Antineoplastic and immunomodulating agents
|
|
|
L01
|
|
|
|
Antineoplastic agents
|
|
|
L02
|
|
|
|
Endocrine therapy
|
|
|
L03
|
|
|
|
Immunostimulants
|
|
|
L04
|
|
|
|
Immunosuppressants
|
| M
|
|
|
|
|
Musculo-skeletal system
|
|
|
M01
|
|
|
|
Anti-inflammatory and antirheumatic products
|
|
|
|
M01A
|
|
|
Anti-inflammatory and antirheumatic products, non-steroids
|
|
|
|
|
M01AA
|
|
Butylpyrazolidines
|
|
|
|
|
M01AB
|
|
Acetic acid derivatives and related substances
|
|
|
|
|
|
M01AB01
|
Indometacin
|
|
|
|
|
|
M01AB02
|
Sulindac
|
|
|
|
|
|
M01AB03
|
Tolmetin
|
|
|
|
|
|
M01AB04
|
Zomepirac
|
|
|
|
|
|
M01AB05
|
Diclofenac
|
|
|
|
|
|
M01AB06
|
Alclofenac
|
|
|
|
|
|
M01AB07
|
Bumadizone
|
|
|
|
|
|
M01AB08
|
Etodolac
|
|
|
|
|
|
M01AB09
|
Lonazolac
|
|
|
|
|
|
M01AB10
|
Fentiazac
|
|
|
|
|
|
M01AB11
|
Acemetacin
|
|
|
|
|
|
M01AB12
|
Difenpiramide
|
|
|
|
|
|
M01AB13
|
Oxametacin
|
|
|
|
|
|
M01AB14
|
Proglumetacin
|
|
|
|
|
|
M01AB15
|
Ketorolac
|
|
|
|
|
|
M01AB16
|
Aceclofenac
|
|
|
|
|
|
M01AB17
|
Bufexamac
|
|
|
|
|
|
M01AB51
|
Indometacin, combinations
|
|
|
|
|
|
M01AB55
|
Diclofenac, combinations
|
|
|
|
|
M01AC
|
|
Oxicams
|
|
|
|
|
M01AE
|
|
Propionic acid derivatives
|
|
|
|
|
M01AG
|
|
Fenamates
|
|
|
|
|
M01AH
|
|
Coxibs
|
|
|
|
|
M01AX
|
|
Other anti-inflammatory and antirheumatic agents, non-steroids
|
|
|
|
M01B
|
|
|
Anti-inflammatory/antirheumatic agents in combination
|
|
|
|
M01C
|
|
|
Specific antirheumatic agents
|
|
|
M02
|
|
|
|
Topical products for joint and muscular pain
|
|
|
M03
|
|
|
|
Muscle relaxants
|
|
|
M04
|
|
|
|
Antigout preparations
|
|
|
M05
|
|
|
|
Drugs for treatment of bone diseases
|
|
|
M09
|
|
|
|
Other drugs for disorders of the musculo-skeletal system
|
| N
|
|
|
|
|
Nervous system
|
|
|
N01
|
|
|
|
Anesthetics
|
|
|
N02
|
|
|
|
Analgesics
|
|
|
N03
|
|
|
|
Antiepileptics
|
|
|
N04
|
|
|
|
Anti-parkinson drugs
|
|
|
N05
|
|
|
|
Psycholeptics
|
|
|
|
N05A
|
|
|
Antipsychotics
|
|
|
|
|
N05AA
|
|
Phenothiazines with aliphatic side-chain
|
|
|
|
|
N05AB
|
|
Phenothiazines with piperazine structure
|
|
|
|
|
N05AC
|
|
Phenothiazines with piperidine structure
|
|
|
|
|
N05AD
|
|
Butyrophenone derivatives
|
|
|
|
|
N05AE
|
|
Indole derivatives
|
|
|
|
|
N05AF
|
|
Thioxanthene derivative
|
|
|
|
|
N05AG
|
|
Diphenylbutylpiperidine derivatives
|
|
|
|
|
N05AH
|
|
Diazepines, oxazepines, thiazepines and oxepines
|
|
|
|
|
N05AL
|
|
Benzamides
|
|
|
|
|
N05AN
|
|
Lithium
|
|
|
|
|
N05AX
|
|
Other antipsychotics
|
|
|
|
|
|
N05AX07
|
Prothipendyl
|
|
|
|
|
|
N05AX08
|
Risperidone
|
|
|
|
|
|
N05AX10
|
Mosapramine
|
|
|
|
|
|
N05AX11
|
Zotepine
|
|
|
|
|
|
N05AX12
|
Aripiprazole
|
|
|
|
|
|
N05AX13
|
Paliperidone
|
|
|
|
|
|
N05AX14
|
Iloperidone
|
|
|
|
N05B
|
|
|
Anxiolytics
|
|
|
|
N05C
|
|
|
Hypnotics and sedatives
|
|
|
N06
|
|
|
|
Psychoanaleptics
|
|
|
N07
|
|
|
|
Other nervous system drugs
|
| P
|
|
|
|
|
Antiparasitic products, insecticides and repellents
|
| R
|
|
|
|
|
Respiratory system
|
| S
|
|
|
|
|
Sensory organs
|
| V
|
|
|
|
|
Various
|
כניסה 
עקבו אחרינו בפייסבוק